about
The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label studyDose-Specific Adverse Drug Reaction Identification in Electronic Patient Records: Temporal Data Mining in an Inpatient Psychiatric PopulationA current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data.Metabolic, endocrinologic and cardiac effects of amisulpride: a 24-week follow-up study.The severe complication of Stevens-Johnson syndrome induced by long-term clozapine treatment in a male schizophrenia patient: a case reportPrevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study.Pharmacological causes of hyperprolactinemiaProlactin and dopamine: what is the connection? A review article.Development and validation of amisulpride in human plasma by HPLC coupled with tandem mass spectrometry and its application to a pharmacokinetic study.Atypical antipsychotics for older adults: are they safe and effective as we once thought?Gastroenterology issues in schizophrenia: why the gut matters.A Perspective on the Primary Care of Patients With Behavior, Mood, and Thought Disturbances: Clinical Applications of Olanzapine.Analysis of Adverse Drug Reactions of Atypical Antipsychotic Drugs in Psychiatry OPDQuetiapine-induced galactorrhea with normal prolactin level in an adult female patient.Self-administered acupressure for treating adult psychiatric patients with constipation: a randomized controlled trial.Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.The relationship between patient satisfaction and treatment outcomes in schizophrenia.The case for long-acting antipsychotic agents in the post-CATIE era.Atypical antipsychotics versus haloperidol for treatment of delirium in acutely ill patients.Iloperidone-induced Galactorrhea in a Middle-aged Female.ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia.Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001-2007: a population-based study of 585,615 deliveries.Atypical antipsychotics in the elderly: a review of therapeutic trends and clinical outcomes.Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder.Reintroduction of clozapine after perforation of the large intestine--a case report and review of the literature.Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies.Predicting pharmacokinetic stability by multiple oral administration of atypical antipsychotics.Comparison of the effect of lithium plus quetiapine with lithium plus risperidone in children and adolescents with bipolar I disorder: a randomized clinical trial.Inhaled Loxapine for Agitation in Intoxicated Patients: A Case Series.Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.Characterization of olanzapine-induced weight gain in rats.Pilot study: access to fitness facility and exercise levels in olanzapine-treated patients.Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine.Self-reported health and physical activity among community mental healthcare users.Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics.
P2860
Q24800019-ABDCD13A-CA7D-4DB4-88F4-91AB85E691A3Q30002404-713CD748-7A74-4C7E-9CF2-C09DA05167BDQ30667146-D7EC75D6-CCF5-4A5A-AE6D-4D2C1DCB78ABQ34037969-5566F85D-1786-4ACD-9EBD-94F812B7AF09Q34473709-A3B80A29-B229-4E2C-A381-800F54513EBDQ34708413-17C71DFC-B77C-4949-8002-03AA754B993CQ34778045-EDDDFC90-7565-40CD-B2C6-F79F0FFBBFEBQ34778434-AC7C9495-B758-4C4E-BAD0-033FF09CA8F3Q35185317-23A43BD6-67EA-4EC2-80B5-46DC242DC635Q35565618-E7A1F9DE-5B99-433E-8AC7-02F3459A7B1FQ35577667-838AAAD6-A007-44DD-93CD-1233D027FB3AQ35666903-905AED31-8B61-43D2-B395-C5611ABE3906Q35732364-7A1C8E52-A7C1-48D8-AA43-597B35E3A074Q36182678-EB551456-A4C4-4539-A578-8CB9CBBA3B41Q36242774-11B48CA3-9D52-4F50-A1BD-72D27E3AB170Q36626247-292931DD-6BC4-48B4-AEE8-81A7849245C9Q36626251-5BF75FAE-2022-437F-A084-9066E23D9294Q36758680-4BAB8DF8-368E-4540-A776-EFCF29FE07D1Q36768269-5E4016AD-E647-4159-B5EA-D162D88DDDFAQ36869411-94748324-34EE-4654-926B-92F144998EFDQ36885358-DDE5A43E-1B33-4419-94F8-D66201F8A9B9Q37026000-A3D6C4A0-D973-4DD4-ADDB-449EC12DA8D7Q37575663-A26BA86E-741E-4A3A-9942-152CDA10C1E4Q37803220-5AEC2A95-B4D4-4E28-930B-F4A26F8A7524Q38113770-372EABD6-B5E1-42CF-8122-0E0DCA3663CFQ38686408-F5E8D493-8C3A-47E0-A8DC-57B2D3C0696EQ40200910-0CD7DBB6-E5B9-45BF-ACD1-2FD094F6F84DQ41686490-8737CDCF-094E-422F-B173-E3A57BCDE90AQ42697689-3FC543AC-98FE-400C-B7B8-20A87D1FE1DBQ44017165-F6463ABD-5CCE-4954-AC67-39043CB75138Q44263522-8096177F-0769-414C-8FB4-242048011BFDQ44664721-6AE3ADC4-C92F-47ED-AC21-681F01E17AFBQ46689242-FA51B351-C802-490D-9DD8-0F1FECE70D13Q46747943-D7DA411F-8A1F-437A-94EE-CE5088152882Q53305566-7DB9DA23-2D1B-4690-B17A-43893CC8BC46
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Tolerability of atypical antipsychotics.
@ast
Tolerability of atypical antipsychotics.
@en
type
label
Tolerability of atypical antipsychotics.
@ast
Tolerability of atypical antipsychotics.
@en
prefLabel
Tolerability of atypical antipsychotics.
@ast
Tolerability of atypical antipsychotics.
@en
P1433
P1476
Tolerability of atypical antipsychotics.
@en
P2093
C Stanniland
P304
P356
10.2165/00002018-200022030-00004
P50
P577
2000-03-01T00:00:00Z
P6179
1030155581